Maxpro Capital Acquisition Corp. (JMAC) Shareholders Approve Apollomics Deal
Maxpro Capital (NASDAQ:JMAC) announced this afternoon that its shareholders have approved its combination with biopharmaceutical firm Apollomics.
An aggregate of 10,804,097 shares of Maxpro’s common stock were present at yesterday’s special meeting. ...READ MORE
